Concho Resources Inc. (CXO) Misled the Investing Public Regarding Optimum Well Spacing and its Ability to Take on Large-Scale Projects   In 2018, Concho constructed the Dominator Project in the

Spectrum Pharmaceuticals, Inc. (SPPI) Materially Misrepresented the Likelihood ROLONTIS Would be Approved by the FDA Spectrum submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”)

Cassava Sciences, Inc. (SAVA) Falsely Touted the Viability and Efficacy of its Lead Drug Candidate     On February 2, 2021, Cassava announced results from its interim analysis of an open-label

HyreCar Inc. (HYRE) Materially Misstated its Insurance Reserves     On May 13, 2021, HyreCar announced “Record First Quarter 2021 Financial Result,” stating that insurance deposits had more than doubled during

Cassava Sciences, Inc. (SAVA) Falsely Touted the Viability and Efficacy of its Lead Drug Candidate     On February 2, 2021, Cassava announced results from its interim analysis of an open-label

Zymergen Inc. (ZY) Made Misstatements Regarding its Business Prospects Zymergen held its IPO on April 23, 2021, raising approximately $530.1 million.  On August 3, 2021, Zymergen issued a business update

View, Inc. (VIEW) Misrepresented its Previously Disclosed Warranty Accruals On November 30, 2020, CF Finance Acquisition Corp. II and View announced they had entered into a definitive merger agreement.  On

Iterum Therapeutics plc (ITRM) Made Misleading Statements Regarding its Drug Candidate     Iterum is developing sulopenem, an anti-infective compound with oral and intravenous formulations that is in Phase III clinical

Yalla Group Limited (YALA) Overstated its User Metrics and Revenue      Yalla Group Limited held its U.S. initial public offering (“IPO”) on September 29, 2020.   The Registration Statement in support